Amgen Generates Q3-2025 Revenue of $560 Million for Tepezza, $213 Million for Pavblu

Amgen, of Thousand Oaks, California, reported Nov. 4 that its Q3-2025 revenue from Tepezza was $560 million, a 15 percent increase over $488 million in Q3-2024.

The total consisted of $518 million in the US and $42 million outside the US.

Amgen said growth was driven by higher inventory levels and a higher net selling price.

The company started recording Tepezza revenue in October 2023.

Amgen reported Q3-2025 revenue for Pavblu, its Eylea biosimilar, of $213 million. The total was made up of $212 million in the US and $1 million outside the US.

The company launched Pavblu in Q4-2024.

AbbVie Reports Q3-2025 Eye Care Revenue of $509 Million

AbbVie, of North Chicago, Illinois, reported Oct. 31 that its Q3-2025 eye care net revenue was $509 million, a 3 percent decline from $525 million in Q3-2024.

Ozurdex revenue was $117 million, a 1.6 percent decline from $119 million in Q3-2024.

AbbVie’s Other Eye Care category, which contains many over-the-counter and prescription products, such as Vuity, as well as devices such as the Xen Gel Stent, generated revenue of $248 million, an 8.8 percent increase over $207 million in Q3-2024.

Hoya Posts Quarterly Medical Segment Revenue of $226.8 Million

Japan-based Hoya Corporation reported Oct. 31 that its medical segment (IOLs, endoscopes, and artificial bone) generated revenue for the third quarter of 2025—its fiscal year Q2-2025—of ¥33.7 billion ($226.8 million, converted Sept. 30, 2025), a 5.9 percent increase over ¥31.8 billion in the same quarter in 2024.

Hoya said intraocular lenses (IOLs) grew 3 percent (0 percent cc) over the same quarter in 2024.

Looking at IOL sales regionally, the company said sales in Japan remained solid for both hospitals and clinics, partly due to new product launches. In Europe, the disruption during core system replacements had subsided, and the company was seeing progress in recovery of demand.

Hoya said sales in China continued to be impacted by the country’s volume-based procurement initiative. Hoya is rebuilding its strategy in China, including the targeting of hospitals.

Overall, the company is focusing on expanding sales of advanced technology IOL products such as trifocal lenses.

Glaukos Reports Q3-2025 Net Sales of $133.5 Million

Glaukos reported Oct. 29 that its Q3-2025 net sales totaled $133.5 million, a 38 percent increase over $96.7 million in Q4-2023.

Glaucoma net sales in Q3-2025 were $110.2 million, a 45 percent increase over $76.0 million in Q3-2024.

Corneal health net sales were $23.3 million, a 13 percent increase over $20.6 million in Q3-2024.

The Aliso Viejo, California, company raised 2025 net sales guidance to $490 million to $495 million, up from $480 million to $486 million previously.

The company also introduced preliminary 2026 net sales guidance of $600 million to $620 million.

Apellis Generates Q3-2025 US Syfovre Revenue of $150.9 Million

Apellis Pharmaceuticals, of Waltham, Massachusetts, reported Oct. 30 that its Q3-2025 US net product revenue for Syfovre was $150.9 million, a 0.72 percent decrease from $152.0 million in Q3-2024.

Apellis launched Syfovre in March 2023.

The company noted that total injections grew 4 percent sequentially over Q2-2025.

In addition, use of Syfovre free goods remained elevated during the quarter and impacted revenue by about $15 million.

Apellis said it delivered about 15 thousand free goods doses of Syfovre and 86 thousand commercial doses to physician offices, for a total of 101 thousand doses, in Q3-2025.

Astellas Reports Quarterly Izervay Revenue of $124 Million

Tokyo, Japan-based Astellas Pharma reported Oct. 30 that its revenue for Izervay in the quarter ended Sept. 30, 2025—Astellas’ second quarter in its fiscal year—was $124 million, a 20.2 percent increase over $103 million in the same quarter in 2024.

The C5 inhibitor for geographic atrophy launched in the US in September 2023.

Tarsus Generates Q3-2025 Xdemvy Revenue of $118.7 Million

Tarsus Pharmaceuticals, of Irvine, California, reported Nov. 4 that its Q3-2025 net product revenue for Xdemvy was $118.7 million, a 147 percent increase over $48.1 million in Q3-2024.

Xdemvy, a treatment for Demodex blepharitis, gained FDA approval in July 2023 and was available for prescription in the US by the end of August 2023.

The company said more than 103 thousand bottles of Xdemvy have been delivered to patients.

Tarsus noted that more than 20 thousand ECPs have written multiple prescriptions, which the company said reflected growing confidence and the consistent integration of Xdemvy into clinical practice.

Lumibird Reports Q3-2025 Medical Division Revenue of $27.1 Million

France-based Lumibird reported Oct. 27 that its Medical Division generated Q3-2025 revenue of €23.1 million ($27.1 million, converted Sept. 30, 2025), a 1.6 percent decline from €23.4 million in Q3-2024.

The company said the Medical Division continued to benefit from direct activities in Australia and Japan. It noted that the strengthening of the sales teams in the US was beginning to bear fruit, but growth in the Americas region was impacted by a temporary slowdown in activity in South America.

Lumibird said it anticipates a high level of activity in Q4-2025, as it does every year.

Ocular Therapeutix Posts Q3-2025 Net Revenue of $14.5 Million

Ocular Therapeutix, of Bedford, Massachusetts, reported Nov. 4 that its Q3-2025 net revenue was $14.5 million, a 5.8 percent decrease from $15.4 million in Q3-2024.

Dextenza product revenue accounted for total revenue.

The company said the decrease was due to a significantly more challenging reimbursement environment for Dextenza in 2025, partially offset by the commercial team successfully driving unit demand.

Xbrane Reports Q3-2025 Revenue for Ximluci of $1.1 Million

Sweden’s Xbrane reported Oct. 24 that Q3-2025 revenue for Ximluci (a biosimilar to Lucentis) was SEK 10.1 million ($1.1 million, converted on Sept. 30, 2025), a 37.7 percent decrease from SEK 16.2 million in Q3-2024.

Ximluci launched in Europe in Q1-2023 and is now available in 24 countries, including 20 in Europe.

Xbrane said Ximluci’s market share in Europe by volume within the ranibizumab market (Lucentis and Lucentis biosimilars) remained at 8 percent.

As for the US market, Xbrane said it is awaiting further information from the FDA to plan the next steps together with the contract manufacturer following a complete response letter outlining unresolved observations from an inspection at one of the manufacturing facilities.

More News

Want to Read Locked Articles?

Already Have an Account?

Register A Corporate Account

Topics of Interest

Products of Interest